VINC
Income statement / Annual
Last year (2024), Vincerx Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Vincerx Pharma, Inc.'s net income was -$30.07 M.
See Vincerx Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$915.00 K
|
$939.00 K
|
$340.00 K
|
$173.00 K
|
$173.00 K
|
| Gross Profit |
$0.00
|
-$915.00 K
|
-$939.00 K
|
-$340.00 K
|
-$173.00 K
|
-$173.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$15.49 M
|
$28.06 M
|
$52.15 M
|
$40.08 M
|
$7.12 M
|
$0.00
|
| General & Administrative Expenses |
$15.98 M
|
$13.64 M
|
$18.95 M
|
$22.58 M
|
$3.60 M
|
$54.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.95 K
|
| Selling, General & Administrative Expenses |
$15.98 M
|
$13.64 M
|
$18.95 M
|
$22.58 M
|
$3.60 M
|
$45.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$31.46 M
|
$41.69 M
|
$71.11 M
|
$62.66 M
|
$10.71 M
|
$45.00 K
|
| Cost And Expenses |
$0.00
|
$42.61 M
|
$71.11 M
|
$62.66 M
|
$10.71 M
|
$45.00 K
|
| Interest Income |
$472.00 K
|
$1.25 M
|
$664.00 K
|
$0.00
|
$54.27 K
|
$54.27 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$915.00 K
|
$939.00 K
|
$340.00 K
|
$0.00
|
$54.00 K
|
| EBITDA |
-$31.46 M |
-$39.24 M |
-$62.05 M |
-$38.97 M |
-$15.85 M |
$9.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.39 M
|
$2.45 M
|
$5.74 M
|
$23.35 M
|
-$5.91 M
|
$0.00
|
| Income Before Tax |
-$30.07 M
|
-$40.16 M
|
-$62.98 M
|
-$39.31 M
|
-$16.62 M
|
-$45.00 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$30.07 M
|
-$40.16 M
|
-$65.37 M
|
-$39.31 M
|
-$16.62 M
|
-$54.00 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.75 |
-6.84 |
-10.86 |
-8.3 |
-11.67 |
-0.0314 |
| EPS Diluted |
-5.75 |
-6.84 |
-10.86 |
-8.3 |
-11.67 |
-0.0314 |
| Weighted Average Shares Out |
$5.23 M
|
$5.87 M
|
$5.80 M
|
$4.74 M
|
$1.42 M
|
$1.43 M
|
| Weighted Average Shares Out Diluted |
$5.23 M
|
$5.87 M
|
$5.80 M
|
$4.74 M
|
$1.42 M
|
$1.43 M
|
| Link |
|
|
|
|
|
|
